NO167203C - Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner.

Info

Publication number
NO167203C
NO167203C NO883204A NO883204A NO167203C NO 167203 C NO167203 C NO 167203C NO 883204 A NO883204 A NO 883204A NO 883204 A NO883204 A NO 883204A NO 167203 C NO167203 C NO 167203C
Authority
NO
Norway
Prior art keywords
preparation
purines
therapeutic active
analogy procedure
piperazinyl derivatives
Prior art date
Application number
NO883204A
Other languages
English (en)
Norwegian (no)
Other versions
NO167203B (no
NO883204L (no
NO883204D0 (no
Inventor
David B R Johnston
Stephen Marburg
Richard L Tolman
Malcolm Maccoss
Laura C Meurer
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO883204D0 publication Critical patent/NO883204D0/no
Publication of NO883204L publication Critical patent/NO883204L/no
Publication of NO167203B publication Critical patent/NO167203B/no
Publication of NO167203C publication Critical patent/NO167203C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO883204A 1987-07-20 1988-07-19 Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner. NO167203C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7536287A 1987-07-20 1987-07-20

Publications (4)

Publication Number Publication Date
NO883204D0 NO883204D0 (no) 1988-07-19
NO883204L NO883204L (no) 1989-01-23
NO167203B NO167203B (no) 1991-07-08
NO167203C true NO167203C (no) 1991-10-16

Family

ID=22125206

Family Applications (1)

Application Number Title Priority Date Filing Date
NO883204A NO167203C (no) 1987-07-20 1988-07-19 Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner.

Country Status (17)

Country Link
EP (1) EP0300726B1 (de)
JP (1) JP2562181B2 (de)
KR (1) KR890002155A (de)
AT (1) ATE94877T1 (de)
AU (1) AU601862B2 (de)
CA (1) CA1341043C (de)
DE (1) DE3884304T2 (de)
DK (1) DK403188A (de)
ES (1) ES2058291T3 (de)
FI (1) FI883423A (de)
HU (1) HU199144B (de)
IL (1) IL87149A (de)
NO (1) NO167203C (de)
NZ (1) NZ225447A (de)
PT (1) PT88029B (de)
YU (1) YU46761B (de)
ZA (1) ZA885242B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
GB8716313D0 (en) * 1987-07-10 1987-08-19 Janssen Pharmaceutica Nv 2-(heterocyclylalkyl)imidazopyridines
GB8922076D0 (en) * 1989-09-28 1989-11-15 Beecham Group Plc Novel process
DK150591D0 (da) * 1991-08-26 1991-08-26 Novo Nordisk As Kemisk forbindelse
WO1993017021A1 (en) * 1992-02-19 1993-09-02 Pfizer, Inc. Heterocyclic compounds for enhancing antitumor activity
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
EP1499598A1 (de) 2002-04-18 2005-01-26 Ucb, S.A. Chemische verbindungen mit zweiteiliger wirkung,verfahren zu deren herstellung und pharmazeutische zusammenstellungen
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
JP4279784B2 (ja) * 2002-12-04 2009-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 1,3−ジヒドロ−イミダゾール縮合環化合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA06002521A (es) 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
AU2004309390B2 (en) 2003-12-22 2011-06-02 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
EP1758895A1 (de) 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin-freisetzende hormonrezeptor-antagonisten
CN1968948A (zh) 2004-06-17 2007-05-23 惠氏公司 用于制备促性腺激素释放激素受体拮抗剂的方法
JP2008524335A (ja) 2004-12-21 2008-07-10 ギリアド サイエンシズ, インコーポレイテッド イミダゾ[4,5−c]ピリジン化合物および抗ウイルス処置法
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
EA015382B1 (ru) 2005-03-08 2011-08-30 Никомед Гмбх Применение рофлумиласта для лечения сахарного диабета типа 2
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
ES2339298T3 (es) 2006-07-07 2010-05-18 Gilead Sciences, Inc. Compuesto de piridazina novedoso y uso del mismo.
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
AU2009269087A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc PI3K isoform selective inhibitors
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
MX2012011164A (es) 2010-03-31 2012-11-12 Lilly Co Eli Compuesto de purina usados como agonistas de cb2.
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
MX2015014757A (es) * 2013-05-02 2016-03-11 Hoffmann La Roche Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2).
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CN104497085B (zh) * 2015-01-16 2017-05-24 华东理工大学 腺苷衍生物及其用途
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1115260B (de) * 1957-02-27 1961-10-19 Thomae Gmbh Dr K Verfahren zur Herstellung von Purinderivaten
GB1186504A (en) * 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
JPS6210085A (ja) * 1985-07-05 1987-01-19 Yoshitomi Pharmaceut Ind Ltd トリフルオロメチルプリン誘導体

Also Published As

Publication number Publication date
DE3884304D1 (de) 1993-10-28
FI883423A0 (fi) 1988-07-19
DE3884304T2 (de) 1994-03-24
NO167203B (no) 1991-07-08
ATE94877T1 (de) 1993-10-15
EP0300726A1 (de) 1989-01-25
NO883204L (no) 1989-01-23
FI883423A (fi) 1989-01-21
HU199144B (en) 1990-01-29
IL87149A0 (en) 1988-12-30
YU46761B (sh) 1994-05-10
KR890002155A (ko) 1989-04-08
NO883204D0 (no) 1988-07-19
ES2058291T3 (es) 1994-11-01
AU601862B2 (en) 1990-09-20
JP2562181B2 (ja) 1996-12-11
PT88029A (pt) 1989-06-30
NZ225447A (en) 1991-12-23
PT88029B (pt) 1995-03-01
CA1341043C (en) 2000-07-04
ZA885242B (en) 1989-03-29
IL87149A (en) 1994-05-30
JPH01104074A (ja) 1989-04-21
EP0300726B1 (de) 1993-09-22
HUT47575A (en) 1989-03-28
DK403188D0 (da) 1988-07-19
AU1923088A (en) 1989-01-27
DK403188A (da) 1989-03-30
YU141088A (en) 1990-10-31

Similar Documents

Publication Publication Date Title
NO167203C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive piperazinyl-derivater av puriner.
DE3466227D1 (en) Insulin derivatives, processes for their preparation, their use and pharmaceutical compositions for the treatment of diabetes mellitus
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
NO171365C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
MY102016A (en) Thiazolidinedione derivatives, their production and use.
DK642587D0 (da) Insulinpraeparat
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
IT1226727B (it) Farmaci precursori della dopamina.
EP0376251A3 (en) An anticoagulant substance obtained from urine
ATE127020T1 (de) Pharmazeutische zusammensetzungen mit eierschalenbestandteilen und ihre herstellung und verwendung.
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
IE890580L (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
DE3586993D1 (de) Kontinuierliche intravenoese infusion von adenosin an menschlichen patienten, einheitsdosierungsform von adenosin und dessen verwendung bei der herstellung von arzneimitteln.
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
EP0324520A3 (de) Alkyl-piperazinyl-5,6-alkylenpyrimidine
KR890001555A (ko) 요산 배설용 조성물
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
González Drug treatment and nutrient therapy: The distinction blurs.
IL87867A0 (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-pyridine derivatives
NO881798D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
DE69109933D1 (de) Verwendung von Mizoribin zur Behandlung oder Vorbeugung der Multiplen Sklerose.